We are happy to announce our latest event being sponsored with Discngine. We welcome Kyle Martin, Postdoctoral Fellow, Boehringer Ingelheim. This will be a in-person event.
Title: In-silico antibody developability: Embedding Dynamics in Intrinsic Physicochemical Profiles Prediction
Date: May 18, 2023
Time: Event time: 5:30 - 8:00PM - Talk promptly starts at 6 pm ET with Q&A immediately afterwards. Please arrive early.
Location: Residence Inn Boston Cambridge
Abstract: To bring an antibody-based medicine to the market, it needs to be stable, safe, and easy to manufacture. Following the concept of holistic in silico developability, Kyle Martin and colleagues have evaluated the molecular properties of antibody-based biotherapeutics in the market, including conformational flexibility of the Fvs using molecular dynamics (MD) simulations. In this event, you will learn how the Developability Navigator In Silico (DENIS) allows researchers to compare monoclonal antibody (mAb) candidates for their similarity with market-stage biotherapeutics in terms of physicochemical properties and conformational stability. This advanced computational tool promises to accelerate the progress of biotherapeutic drug candidates from discovery into early development by predicting drug properties in different aqueous environments.
Presenter: Kyle Martin, Postdoctoral Fellow, Boehringer Ingelheim
Bio: Dr. Martin got his PhD in biophysics from the University of Idaho in 2020 where his research ranged from predicting Ebola virus escape mutants to protein stability in the subsurface ocean of Saturn’s moon Titan. He started his postdoctoral research at Boehringer Ingelheim in 2020. His postdoctoral research has focused on antibody design via in-silico tools including molecular dynamics and predictive models. He’s published 2 papers as a co-author and 1 paper as a main author while at Boehringer.
Reference: https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.2c00838
No comments:
Post a Comment